Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study

NCT: NCT05106608 · RECRUITING

NCT IDNCT05106608
StatusRECRUITING
Start Date2022-07-13
Completion2028-07
SponsorUniversidad de Granada (OTHER)
First posted
Last updated

Brief Summary

The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.

Frequently Asked Questions

What is Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study?

Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study is a clinical trial registered under NCT05106608. Current status: RECRUITING.

What is the status of NCT05106608?

The current status of NCT05106608 (Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study) is: RECRUITING.

When did Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study start?

Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study started on 2022-07-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑